MRK Stock Recent News
MRK LATEST HEADLINES
Merck & Co Inc's (NYSE:MRK, ETR:6MK) experimental treatment for respiratory syncytial virus (RSV) has shown positive results in a mid- to late-stage trial, moving the company closer to seeking regulatory approval. The treatment, clesrovimab, aims to protect infants from RSV, a leading cause of hospitalizations in newborns and responsible for hundreds of infant deaths annually.
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Infants.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's CAPVAXIVE (Pneumo. 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease.
The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.
ALAMEDA, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis' investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a phase 3 pivotal trial for the treatment of patients with head and neck squamous cell car.
There's doubtlessly some coming uncertainty for both, but the prices are right.
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Activated Polyethylene Glycol Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The global activated polyethylene glycol market is expected to reach an estimated $162 million by 2030 with a CAGR of 2.4% from 2024 to 2030. The major drivers for this market are the chemical and pharmaceutical sectors are expanding quickly, rapid advancement in molecular biology and biotechnology, as well as, growing acceptance of water-based paints, varnishes, and inks due to their wider range of applications in the automotive and building sectors. The future of the global activated polyethylene glycol market looks promising with opportunities in the pharmaceutical intermediate and medical device markets.
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for continued growth and extended patent protection through a subcutaneous formulation. Strategic acquisitions are broadening Merck's pipeline and should reduce its reliance on Keytruda, despite the short-term profit impacts.